Nova Mentis Life Science Corp., a biotechnology business focusing on creating innovativ psilocybin-based treatment for neuroinflammatory illnesses as well as Mycrodose Therapeutics. NOVA’s psilocybin-based drug development program has been successfully merged with Mycrodose’s transdermal technology, according to the business focusing on creating innovative drug delivery systems for use with psychedelic chemicals.
Mycrodose Therapeutics’ facilities in San Diego, CA are conducting the first permeation experiments on human skin to demonstrate that NOVA’s medicinal molecule may be effectively administered through human skin utilizing Mycrodose’s transdermal technology. Neuroinflammatory diseases, such as Fragile X Syndrome, the most prevalent genetic cause of Autism Spectrum Disorder, may not require a high dose of psychedelic substance or a huge macrodose quantity of medicine to assist a patient therapeutically, according to the firms.
Nova performed four preclinical investigations that confirmed the therapeutic effects of its patented psilocybin-based medication and established a microdose therapeutic threshold for psilocybin that may be employed in future human trials. Nova is the first biotech firm to acquire orphan drug status for psilocybin FXS in the United States and the European Union, which will considerably expedite the business’s journey to medication approval.